Novo builds clinical case for diabetes combo
Novo Nordisk has presented new, positive data for combination treatment Xultophy, showing that the new option for diabetes patients is superior to an older treatment in a number of ways.
BY STEFAN SINGH KAILAY
Fresh data presented by Novo Nordisk should help build the case for its new diabetes treatment Xultophy with payers and doctors.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Welcome news for Novo as diabetes combo wins US approval
For abonnenter
Zealand's big money dreams can finally come true
For abonnenter
Novo EVP: Negotiations can begin now
For abonnenter
